フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
N -- Full year net sales for continuing operations1 up 9% (cc2, +6% USD): -- Pharmaceuticals BU growing 12% (cc) driven by Cosentyx USD 3.6...
N -- Der Nettoumsatz der fortzuführenden Geschäftsbereiche1 steigt 2019 um 9% (kWk2, +6% USD): -- Die Geschäftseinheit...
N -- Hausse du chiffre d'affaires net des activités poursuivies1 de 9% sur l'exercice entier (tcc2, +6% USD): -- Pharmaceuticals:...
N Basel, January 6, 2020 -- Novartis AG (NYSE: NVS) ("Novartis") today announced the successful completion of the previously announced...
N -- Pooled analyses of LUSTER 1 and 2 did not support further development of Fevipiprant in asthma as a primary indication -- Fevipiprant was...
N Basel, December 5, 2019 -- Novartis AG (NYSE: NVS) ("Novartis") today announced that its indirect wholly-owned subsidiary, Medusa...
N -- Over 50 million secondary prevention patients worldwide with atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia...
N -- Sickle cell pain crises are unpredictable, severe events associated with life-threatening complications1 -- Adakveo reduced the annual rate...
N -- Cosentyx narrowly missed statistical significance for superiority in ACR 20, the primary endpoint of the EXCEED trial, while showing...
N -- FDA placed a partial hold on AVXS-101 intrathecal clinical trials for SMA patients based on findings in a small pre-clinical animal study...
N -- Continuing operations2 net sales up 13% (cc1, +10% USD) driven by: -- Cosentyx sales of USD 937 million (+27% cc), with strong demand across...
N -- Chiffre d'affaires net des activités poursuivies2 en hausse de 13% (tcc1, +10% USD) soutenu par: -- Cosentyx: USD 937 millions...
N -- Der Nettoumsatz der fortzuführenden Geschäftsbereiche2 steigt aufgrund folgender Beiträge um 13% (kWk1, +10% USD): -- Cosentyx...
N -- In two head-to-head clinical trials, patients on Beovu (brolucizumab) achieved vision gains that were non-inferior to aflibercept at year one...
N -- Phase III PREVENT study met 52-week primary endpoint of ASAS40, showing a sustained response in patients with non-radiographic axial...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
サインアップして広告なしのエクスペリエンスを体験してください
今すぐ試してください
広告を残す